We present a microfluidic device to expose cancer cells to a dynamic, in vivo-like concentration profile of a drug, and quantify efficacy on-chip.
The available active surface area and the density of probes immobilized on this surface are responsible for achieving high specificity and sensitivity in electrochemical biosensors that detect biologically relevant molecules, including DNA. Here, we report the design of gold-coated, silicon micropillar-structured electrodes functionalized with modified poly-l-lysine (PLL) as an adhesion layer to concomitantly assess the increase in sensitivity with the increase of the electrochemical area and control over the probe density. By systematically reducing the center-to-center distance between the pillars (pitch), denser micropillar arrays were formed at the electrode, resulting in a larger sensing area. Azido-modified peptide nucleic acid (PNA) probes were click-reacted onto the electrode interface, exploiting PLL with appended oligo(ethylene glycol) (OEG) and dibenzocyclooctyne (DBCO) moieties (PLL-OEG-DBCO) for antifouling and probe binding properties, respectively. The selective electrochemical sandwich assay formation, composed of consecutive hybridization steps of the target complementary DNA (cDNA) and reporter DNA modified with the electroactive ferrocene functionality (rDNA-Fc), was monitored by quartz crystal microbalance. The DNA detection performance of micropillared electrodes with different pitches was evaluated by quantifying the cyclic voltammetric response of the surface-confined rDNA-Fc. By decrease of the pitch of the pillar array, the area of the electrode was enhanced by up to a factor 10.6. A comparison of the electrochemical data with the geometrical area of the pillared electrodes confirmed the validity of the increased sensitivity of the DNA detection by the design of the micropillar array.
One of the key aspects of surviving cancer is to detect the disease as early as possible, thereby enlarging the window of opportunity of curing it. [4,5] A recent trend for early cancer diagnostics is the pre-symptomatic detection of cancer biomarkers in liquid biopsy samples and, therefore, improving the survival rate. [6,7] Hypermethylated DNA (hmDNA) is one of the typical biomarkers found in liquid biopsy samples of cancer patients. [8,9] The presence of hmDNA in blood and urine is correlated to multiple types of cancer, including gastric, lung and ovarian cancer. [10][11][12][13] From a genetic point of view, DNA methylation takes place predominantly at promotor regions with a relative high amount of cytosine bases that are followed directly by a guanine (CpGs) in the 5′-to-3′ direction, the so-called CpG-rich regions. [13] The methylation of a CpG is an epigenetic alternation in which a methyl group is covalently bonded to the cytosine base at the fifth carbon. By CpG methylation, gene expressions are controlled in cells. As a consequence, methylation can play a role in tumor development when tumor suppressor genes are methylated, thereby repressing the transcription and thus silencing these genes. [14] Hypermethylation refers to the situation that methylation of a promotor region occurs, which in a healthy situation does not occur.Early disease detection as well as disease progress and the effectiveness of a therapy can be monitored by measuring the hmDNA concentration over time. [15] Yet, the concentration of hmDNA, especially in early-stage cancers, can be as low as a few DNA copies per liquid biopsy sample. [16][17][18] The current approach to measure hmDNA employs DNA isolation and bisulfite conversion, making it time-consuming and labor intensive. As a result, the method is not widely applicable in the clinic. Typically, hmDNA is detected in bisulfite-treated DNA samples by quantitative polymerase chain reaction (PCR) (qPCR, of the region of interest; can be cancer dependent). Alternative hmDNA detection approaches that may be suitable for use in point-of-care applications, include electrochemistry, [19] CRISPR [20] and isothermal amplification. [21] The detection of specific hmDNA biomarkers by sequencing or biosensing approaches involves the ability to distinguish between hmDNA and non-methylated DNA. [22][23][24] Commonly a preselection step is applied, and three different approaches exist in order to differentiate between hmDNA and non-methylatedThe preselection of hypermethylated DNA (hmDNA) from liquid biopsy samples is key to enable early-stage cancer diagnostics. Due to limited selectivity of the existing preselection approaches, however, wide integration in the clinic is currently prohibited. Here, it is argued that an affinity method on a surface, such as used in affinity chromatography, can be significantly improved by employing the principles of multivalency and superselectivity. In the here proposed method, a methyl binding domain (MBD) protein immobilized at a surface is used as a recepto...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.